Immunotherapy in Hepatocellular Carcinoma

Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Formato:	Online
Lenguaje:	inglés
Publicado:	MDPI - Multidisciplinary Digital Publishing Institute 2023
Materias:	cancer immunotherapy TCGA mutations copy number variations microRNAs PD-1 PD-L1 hepatocellular carcinoma predictive factors immunotherapy immune checkpoint inhibition check-point inhibitors liver disease outcome biomarkers combination immunotherapy immune-related adverse events (irAEs) hepatocellular carcinoma (HCC) alpha fetoprotein response immune checkpoint inhibitor unresectable hepatocellular carcinoma a disintegrin and metalloprotease 9 nivolumab natural killer CTLA-4 combination therapy PD-1 antibody PD-L1 antibody anti-VEGF inhibitor molecular classification immune phenotype stem cell marker oncogenic signal β-catenin genetic alteration liver cancer effectiveness safety HCC molecular-targeted agent TACE tyrosine kinase inhibitor CD14+ cells programmed death 1 ligands translational approaches combination therapies therapy resistance predictive markers tissue-resident memory CD8 T cells immune checkpoint blockade thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
Acceso en línea:	ONIX_20230511_9783036566917_39
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Immunotherapy in Hepatocellular Carcinoma

Ejemplares similares